Literature DB >> 10697538

Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines.

A Opolski1, J Wietrzyk, A Chrobak, E Marcinkowska, E Wojdat, A Kutner, C Radzikowski.   

Abstract

The antiproliferative in vitro activity of side-chain modified analogues of 1,25-dihydroxyvitamin D3 was examined in order to select compounds with potential antitumour activity. Analogues PRI-1906, PRI-1907, PRI-1909, PRI-2191, PRI-2192, PRI-2193 and PRI-2194 were examined for their antiproliferative activity in vitro against a spectrum of various human cancer cell lines using the MTT technique. In addition, analogues PRI-1906 and PRI-2191 were screened against cells of human leukaemia HL-60 line and against normal human skin fibroblasts. Calcitriol and these two analogues revealed strong antiproliferative activity against these two targets with maximal growth inhibition of 68% for HL-60 cells and of 60% for fibroblasts, and this effect was dose dependent. All analogues tested, except PRI-1909, revealed antiproliferative activity against human carcinoma cell lines of breast origin applied, namely against T47D and MCF-7. The maximal growth inhibition of 49% for T47D cell line and 39% for MCF-7 line was observed, and this effect was dose dependent. The inhibitory doses of the analogues tested were compared with the indices for calcitriol. Analogue PRI-1906 revealed the strongest antiproliferative activity against these four target cell lines (HL-60, fibroblasts, MCF-7, and T47D). The novel analogues of calcitriol, similarly to calcitriol, appeared to be not active against other human cancer cell lines tested (including those originated from lung, colon, prostate, urinary bladder, ovary, pancreas, stomach and kidney) revealing an antiproliferative activity not exceeding 20%. The mechanism of the observed antiproliferative effect of calcitriol and its analogues in vitro remains unclear, however, it may be related to their effect on cell differentiation. The appearance of antigen CD14 and CD11b expression after exposure to calcitriol and its new analogues confirmed their effect on cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10697538

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

Authors:  David Jarrard; Badrinath Konety; Wei Huang; Tracy Downs; Jill Kolesar; Kyung Mann Kim; Tom Havighurst; Joel Slaton; Margaret G House; Howard L Parnes; Howard H Bailey
Journal:  Am J Clin Exp Urol       Date:  2016-09-20

2.  Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy.

Authors:  T M Goszczyński; B Filip-Psurska; K Kempińska; J Wietrzyk; J Boratyński
Journal:  Pharmacol Res Perspect       Date:  2014-05-06

3.  Prodifferentiation Activity of Novel Vitamin D₂ Analogs PRI-1916 and PRI-1917 and Their Combinations with a Plant Polyphenol in Acute Myeloid Leukemia Cells.

Authors:  Matan Nachliely; Ehud Sharony; Narasimha Rao Bolla; Andrzej Kutner; Michael Danilenko
Journal:  Int J Mol Sci       Date:  2016-07-05       Impact factor: 5.923

4.  Differential Impact of Calcitriol and Its Analogs on Tumor Stroma in Young and Aged Ovariectomized Mice Bearing 4T1 Mammary Gland Cancer.

Authors:  Artur Anisiewicz; Agata Pawlik; Beata Filip-Psurska; Joanna Wietrzyk
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

5.  Regulation of Leukemic Cell Differentiation through the Vitamin D Receptor at the Levels of Intracellular Signal Transduction, Gene Transcription, and Protein Trafficking and Stability.

Authors:  Elżbieta Gocek; Hanna Baurska; Aleksandra Marchwicka; Ewa Marcinkowska
Journal:  Leuk Res Treatment       Date:  2012-05-14

6.  Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model.

Authors:  Magdalena Milczarek; Mateusz Psurski; Andrzej Kutner; Joanna Wietrzyk
Journal:  BMC Cancer       Date:  2013-06-18       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.